Danaher (DHR) Q3 2026 (USD): Adj. EPS 2.11 (exp. 1.92), Revenue 6.6bln (exp. 6.56bln); FY Outlook Adj. EPS 8.57-8.62 (exp. 8.50, prev. guided 8.45-8.60)

• For the fourth quarter 2026, the Company anticipates that non-GAAP core revenue excluding respiratory revenue will increase in the 4.0% to 5.0% range year-over-year.
• We expect respiratory revenue to be an approximately 150 basis point headwind, resulting in core revenue growth of approximately 3.0%.

A beat on adjusted EPS with a modest revenue upside and a small raise to full-year guidance fits the established pattern for the life sciences tools complex, where quarterly prints have tended to matter less than the direction of core organic growth and the shape of the bioprocessing and biotech funding recovery. The distinction Danaher draws between core revenue excluding respiratory and reported core growth is the recurring tell: respiratory testing swings at its diagnostics arm have distorted comparability for several reporting cycles, and management framing around ex-respiratory growth is where peers and analysts have anchored the underlying trend. A guidance raise of this size, toward the top end of the prior range rather than a step-change, has historically been read as incremental confirmation rather than a re-rating event, particularly when the accompanying quarter is already largely discounted. Read-throughs have typically extended to the closest peer in the tools space and to smaller consumables names, given Danaher's recurring-revenue mix is treated as a bellwether for lab demand. What tends to follow is the call commentary on order trends and China exposure, which in past episodes has moved the stock more than the headline beat itself.